Related Experiment Videos
New designs for the selection of treatments to be tested in randomized clinical trials
R Simon1, P F Thall, S S Ellenberg
1Biometric Research Branch, National Cancer Institute, Rockville, MD 20852.
Abstract:
The most important aspect of phase III randomized clinical trials is the selection of the experimental treatments to be tested. Often this decision is based on uncontrolled phase II trials. Substantial statistical attention has been focused on the design of phase III trials and for simple phase II trials, which determine whether a new drug has any anti-disease activity. Much less statistical effort has been devoted to the design and analysis of phase II trials for screening active experimental treatments to determine whether they are sufficiently active, relative to standard treatments, to warrant the conduct of a large randomized phase III trial. This problem is particularly acute in the development of drug combinations where many regimens are possible. We review several designs for such screening trials which we have developed.
Insights
Selecting effective experimental treatments for phase III clinical trials is crucial. This study reviews statistical designs for phase II screening trials to identify promising drug combinations for further testing.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Drug Development
Background:
- Phase III clinical trials are critical for evaluating new treatments, but their success hinges on selecting appropriate experimental therapies.
- Current statistical focus often prioritizes phase III trial design and simple phase II trials assessing anti-disease activity.
- Less attention has been given to phase II trial designs for screening and selecting treatments that warrant larger phase III studies, especially for drug combinations.
Purpose of the Study:
- To address the statistical challenges in designing phase II screening trials for experimental treatments.
- To present and review novel designs for phase II trials focused on identifying sufficiently active treatments for phase III progression.
- To specifically tackle the complexities of screening drug combinations in early-phase trials.
Main Methods:
- Review of existing and newly developed statistical designs for phase II screening trials.
- Focus on methods for comparing experimental treatments against standard care to ensure clinical relevance.
- Consideration of designs suitable for the high-dimensional problem of testing multiple drug combinations.
Main Results:
- Identified a gap in statistical methodology for phase II screening trials compared to phase III and simple phase II trials.
- Proposed and reviewed several innovative designs tailored for the efficient screening of experimental treatments.
- Highlighted the particular need for such designs in the context of developing drug combinations.
Conclusions:
- Effective phase II screening trial designs are essential for optimizing the selection of treatments for phase III trials.
- The reviewed designs offer statistical frameworks to improve the identification of promising drug candidates, especially in combination therapy development.
- Further statistical development in phase II screening is needed to enhance drug development efficiency.